Nuveen
ELDN icon

Nuveen’s Eledon Pharmaceuticals ELDN Stock Holding History

Nuveen’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824K Buy
209,097
+132,805
+174% +$483K ﹤0.01% 3039
2026
Q1 		$235K Hold
76,292
– – ﹤0.01% 3066
2025
Q4 		$115K Hold
76,292
– – ﹤0.01% 3204
2025
Q3 		$198K Hold
76,292
– – ﹤0.01% 3153
2025
Q2 		$207K Buy
+76,292
New +$229K ﹤0.01% 3150

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Nuveen's ELDN Position: Q2 2026 in Review

Nuveen increased its Eledon Pharmaceuticals (ELDN) stake by 174% in Q2 2026, buying an estimated $483K and bringing the position to 209,097 shares worth $824K. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

Nuveen first reported a position in ELDN in Q2 2025 and has held it in 5 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Nuveen held 209,097 shares of Eledon Pharmaceuticals worth $824K as of Q2 2026.
  • Nuveen bought 132,805 Eledon Pharmaceuticals shares in Q2 2026, an estimated $483K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3039 holding.
  • Nuveen first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.